Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADG116 plus Pembrolizumab in Advanced Solid Tumors
NCT05277402Phase 1Completed
- Sponsor
- Adagene
- Start
- Feb 2022
- Primary completion
- Aug 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of adg116 in solid tumor, sponsored by Adagene. Primary endpoints: Dose-limiting toxicity at 9 months, Recommended Phase 2 Dose at 9 months and 1 more. Started Feb 2022; status: completed.
02
Drugs
adg116
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05277402.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05277402.